Abstract: Alzheimer’s disease (AD) is a complex, progressive neurodegenerative disorder and the leading cause of dementia worldwide. It is characterized by the accumulation of extracellular amyloid–beta (Aβ) plaques and intracellular tau neurofibrillary tangles, leading to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes can begin decades before clinical symptoms emerge, highlighting the critical need for early, accessible, and accurate diagnostic tools. Traditionally, AD diagnosis has relied on clinical assessments supported by neuroimaging and cerebrospinal fluid (CSF) biomarkers, which are accurate but costly and invasive (Jack et al., 2024). However, recent advancements in bloodbased biomarkers (BBMs) have opened a new frontier in AD diagnostics, offering a minimally invasive, cost-effective, and scalable approach to early detection and disease monitoring (Hunter et al., 2025). The 2024 Alzheimer’s Association guidelines mark a turning point by recognizing BBMs as core diagnostic tools alongside amyloid positron emission tomography (PET) imaging and CSF biomarkers (Jack et al., 2024). Here, we discuss the potential of BBMs in AD diagnosis, the technological advancements driving their development, and the key challenges that remain for their widespread clinical implementation.